About Tempus AI, Inc.
https://www.tempus.comTempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
CEO
Eric P. Lefkofsky
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 180
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Canaccord Genuity
Buy
BTIG
Buy
HC Wainwright & Co.
Buy
Needham
Buy
Guggenheim
Buy
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BAILLIE GIFFORD & CO
Shares:9.69M
Value:$671.49M
VANGUARD GROUP INC
Shares:9.44M
Value:$654.11M
ARK INVESTMENT MANAGEMENT LLC
Shares:7.18M
Value:$497.14M
Summary
Showing Top 3 of 451
About Tempus AI, Inc.
https://www.tempus.comTempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $334.21M ▲ | $265.85M ▲ | $-79.98M ▼ | -23.93% ▼ | $-0.46 ▼ | $-37.28M ▼ |
| Q2-2025 | $314.63M ▲ | $256.81M ▲ | $-42.84M ▲ | -13.62% ▲ | $-0.25 ▲ | $9.08M ▲ |
| Q1-2025 | $255.74M ▲ | $223.89M ▲ | $-68.04M ▼ | -26.6% ▼ | $-0.4 ▼ | $-73.98M ▼ |
| Q4-2024 | $200.68M ▲ | $172.76M ▲ | $-13.01M ▲ | -6.48% ▲ | $-0.08 ▲ | $12.46M ▲ |
| Q3-2024 | $180.93M | $159.46M | $-75.84M | -41.92% | $-0.46 | $-50.91M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $759.64M ▲ | $2.28B ▲ | $1.77B ▲ | $507.82M ▲ |
| Q2-2025 | $291.31M ▲ | $1.63B ▲ | $1.32B ▲ | $309.56M ▼ |
| Q1-2025 | $218.79M ▼ | $1.54B ▲ | $1.22B ▲ | $326.19M ▲ |
| Q4-2024 | $448.26M ▼ | $926.12M ▼ | $869.78M ▼ | $56.34M ▲ |
| Q3-2024 | $466.32M | $971.73M | $918M | $53.73M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-79.98M ▼ | $-119.84M ▼ | $-2.31M ▲ | $594.69M ▲ | $472.5M ▲ | $-126.55M ▼ |
| Q2-2025 | $-42.84M ▲ | $44.16M ▲ | $-9.51M ▲ | $0 ▼ | $34.73M ▲ | $34.65M ▲ |
| Q1-2025 | $-68.04M ▼ | $-105.62M ▼ | $-375.82M ▼ | $293.04M ▲ | $-188.51M ▼ | $-109M ▼ |
| Q4-2024 | $-13.01M ▲ | $-39.25M ▼ | $-7.96M ▲ | $-179K ▲ | $-47.04M ▲ | $-47.21M ▼ |
| Q3-2024 | $-75.84M | $48.66M | $-131.41M | $-8.12M | $-90.79M | $48.62M |
CEO
Eric P. Lefkofsky
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 180
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Canaccord Genuity
Buy
BTIG
Buy
HC Wainwright & Co.
Buy
Needham
Buy
Guggenheim
Buy
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BAILLIE GIFFORD & CO
Shares:9.69M
Value:$671.49M
VANGUARD GROUP INC
Shares:9.44M
Value:$654.11M
ARK INVESTMENT MANAGEMENT LLC
Shares:7.18M
Value:$497.14M
Summary
Showing Top 3 of 451